Sarepta Therapeutics (SRPT) Cash from Restructuring (2016)
Sarepta Therapeutics (SRPT) posted quarterly Cash from Restructuring of $407000.0 for Q4 2016, up 51.3% quarter-over-quarter from $269000.0 in Q3 2016.
Sarepta Therapeutics (SRPT) Cash from Restructuring (2016) Analysis & Trends
Sarepta Therapeutics' Cash from Restructuring history runs 1 years deep, the most recent figure standing at $407000.0 for Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 407,000.00 |
| Sep 30, 2016 | 269,000.00 |